The Experts below are selected from a list of 2454 Experts worldwide ranked by ideXlab platform

Andrea J. Rapkin - One of the best experts on this subject based on the ideXlab platform.

  • emotion regulation in women with premenstrual Dysphoric Disorder
    Archives of Womens Mental Health, 2016
    Co-Authors: Nicole Petersen, Edythe D. London, Letty Liang, Dara G Ghahremani, Rachel Gerards, Linda Goldman, Andrea J. Rapkin
    Abstract:

    Premenstrual Dysphoric Disorder (PMDD) is a psychiatric Disorder that causes serious impairments in the functioning and quality of life of affected women. Until recently, research efforts were somewhat hampered by the lack of formal diagnostic criteria, which have now been codified as a category in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Better characterization of deficits in socioemotional functioning caused by PMDD may aid in improving treatment efforts. In this investigation, prospective symptom ratings, based on DSM-5 criteria, were used to measure PMDD symptoms in 36 women (18 with PMDD and 18 healthy controls). Two self-report inventories, the Emotion Regulation Questionnaire and the Difficulties in Emotion Regulation Scale, were used to measure ability to regulate emotions, and socioemotional functioning was measured by inventories of social connectedness, perceived stress, and affect. Potential relationships between ability to regulate emotion and PMDD symptom severity, as well as other measures of socioemotional functioning and affective state, were tested. Women with PMDD reported significantly more behavioral impulsivity and greater difficulties in regulating emotion and in socioemotional functioning. Cognitive or behavioral strategies to improve these problems may benefit women with PMDD and help to alleviate distress caused by this Disorder.

  • the cerebellum and premenstrual Dysphoric Disorder
    neuroscience 2014 Vol. 1 Pages 120-141, 2014
    Co-Authors: Andrea J. Rapkin, Steven M. Berman, Edythe D. London
    Abstract:

    The cerebellum constitutes ten percent of brain volume and contains the majority of brain neurons. Although it was historically viewed primarily as processing motoric computations, current evidence supports a more comprehensive role, where cerebro-cerebellar feedback loops also modulate various forms of cognitive and affective processing. Here we present evidence for a role of the cerebellum in premenstrual Dysphoric Disorder (PMDD), which is characterized by severe negative mood symptoms during the luteal phase of the menstrual cycle. Although a link between menstruation and cyclical dysphoria has long been recognized, neuroscientific investigations of this common Disorder have only recently been explored. This article reviews functional and structural brain imaging studies of PMDD and the similar but less well defined condition of premenstrual syndrome (PMS). The most consistent findings are that women with premenstrual dysphoria exhibit greater relative activity than other women in the dorsolateral prefrontal cortex and posterior lobules VI and VII of the neocerebellum. Since both brain areas have been implicated in emotional processing and mood Disorders, working memory and executive functions, this greater activity probably represents coactivation within a cerebro-cerebellar feedback loop regulating emotional and cognitive processing. Some of the evidence suggests that increased activity within this circuit may preserve cerebellar structure during aging, and possible mechanisms and implications of this finding are discussed.

  • treatment of premenstrual Dysphoric Disorder
    Women's Health, 2013
    Co-Authors: Andrea J. Rapkin, Erin I Lewis
    Abstract:

    Premenstrual Dysphoric Disorder (PMDD) is comprised of a cluster of affective, behavioral and somatic symptoms recurring monthly during the luteal phase of the menstrual cycle. The Disorder affects 3–8% of menstruating women and represents the more severe and disabling end of the spectrum of premenstrual Disorders, which includes premenstrual syndrome and premenstrual aggravation of underlying affective Disorder. Rigorous and specific diagnostic criteria for PMDD were specified in the Diagnostic and Statistical Manual of Mental Disorders IV (1994) and reaffirmed in the Diagnostic and Statistical Manual of Mental Disorders V (2013) and, consequently, there has been a marked increase in well-designed, placebo-controlled studies evaluating treatment modalities. Although the exact pathogenesis of PMDD is still elusive, treatment of PMDD and severe premenstrual syndrome has centered on neuromodulation via serotonin reuptake inhibitor antidepressants, and ovulation suppression utilizing various contraceptive an...

  • premenstrual Dysphoric Disorder and severe premenstrual syndrome in adolescents
    Pediatric Drugs, 2013
    Co-Authors: Andrea J. Rapkin, Judith A Mikacich
    Abstract:

    Numerous epidemiologic studies have demonstrated that premenstrual Disorders (PMDs) begin during the teenage years. At least 20 % of adolescents experience moderate-to-severe premenstrual symptoms associated with functional impairment. Premenstrual syndrome (PMS) consists of physical and/or psychological premenstrual symptoms that interfere with functioning. Symptoms are triggered by ovulation and resolve within the first few days of menses. The prevalence of premenstrual Dysphoric Disorder (PMDD), a severe form of PMS accompanied by affective symptoms, is likely equal to or higher than in adults. The diagnosis of a PMD requires a medical and psychological history and physical examination but it is the daily prospective charting of bothersome symptoms for two menstrual cycles that will clearly determine if the symptoms are related to a PMD or to another underlying medical or psychiatric diagnosis. The number and type of symptoms are less important than the timing. Randomized controlled trials of pharmacologic treatments in teens with moderate-to-severe PMS and PMDD have yet to be performed. However, clinical experience suggests that treatments that are effective for adults can be used in adolescents. PMS can be ameliorated by education about the nature of the Disorder, improving calcium intake, performing exercise and reducing stress, but to treat severe PMS or PMDD pharmacologic therapy is usually required. Eliminating ovulation with certain hormonal contraceptive formulations or gonadotropin-releasing hormone agonists will be discussed. Serotonergic agonists are a first-line therapy for adults, and some serotonin reuptake inhibitors such as fluoxetine and escitalopram can be administered safely to teens.

  • pathophysiology of premenstrual syndrome and premenstrual Dysphoric Disorder
    Menopause International, 2012
    Co-Authors: Andrea J. Rapkin, A L Akopians
    Abstract:

    Premenstrual syndrome (PMS) and premenstrual Dysphoric Disorder are triggered by hormonal events ensuing after ovulation. The symptoms can begin in the early, mid or late luteal phase and are not associated with defined concentrations of any specific gonadal or non-gonadal hormone. Although evidence for a hormonal abnormality has not been established, the symptoms of the premenstrual Disorders are related to the production of progesterone by the ovary. The two best-studied and relevant neurotransmitter systems implicated in the genesis of the symptoms are the GABArgic and the serotonergic systems. Metabolites of progesterone formed by the corpus luteum of the ovary and in the brain bind to a neurosteroid-binding site on the membrane of the gamma-aminobutyric acid (GABA) receptor, changing its configuration, rendering it resistant to further activation and finally decreasing central GABA-mediated inhibition. By a similar mechanism, the progestogens in some hormonal contraceptives are also thought to adversely affect the GABAergic system. The lowering of serotonin can give rise to PMS-like symptoms and serotonergic functioning seems to be deficient by some methods of estimating serotonergic activity in the brain; agents that augment serotonin are efficacious and are as effective even if administered only in the luteal phase. However, similar to the affective Disorders, PMS is ultimately not likely to be related to the dysregulation of individual neurotransmitters. Brain imaging studies have begun to shed light on the complex brain circuitry underlying affect and behaviour and may help to explicate the intricate neurophysiological foundation of the syndrome.

Kimberly A Yonkers - One of the best experts on this subject based on the ideXlab platform.

  • premenstrual Dysphoric Disorder evidence for a new category for dsm 5
    American Journal of Psychiatry, 2012
    Co-Authors: Neill C Epperson, Peter Schmidt, Elias Eriksson, Meir Steiner, Ann S Hartlage, Ian Jones, Kimberly A Yonkers
    Abstract:

    Premenstrual Dysphoric Disorder, which affects 2%–5% of premenopausal women, was included in Appendix B of DSM-IV, “Criterion Sets and Axes Provided for Further Study.” Since then, aided by the inclusion of specific and rigorous criteria in DSM-IV, there has been an explosion of research on the epidemiology, phenomenology, pathogenesis, and treatment of the Disorder. In 2009, the Mood Disorders Work Group for DSM-5 convened a group of experts to examine the literature on premenstrual Dysphoric Disorder and provide recommendations regarding the appropriate criteria and placement for the Disorder in DSM-5. Based on thorough review and lengthy discussion, the work group proposed that the information on the diagnosis, treatment, and validation of the Disorder has matured sufficiently for it to qualify as a full category in DSM-5. A move to the position of category, rather than a criterion set in need of further study, will provide greater legitimacy for the Disorder and encourage the growth of evidence-based research, ultimately leading to new treatments.

  • update on research and treatment of premenstrual Dysphoric Disorder
    Harvard Review of Psychiatry, 2009
    Co-Authors: Joanne Cunningham, Kimberly A Yonkers, Shaughn Obrien, Elias Eriksson
    Abstract:

    Many women in their reproductive years experience some mood, behavioral. or physical symptoms in the week prior to menses. Variability exists in the level of symptom burden in that some women experience mild symptoms, whereas a small minority experience severe and debilitating symptoms. For an estimated 5%-8% of premenopausal women, work or social functioning are affected by severe premenstrual syndrome. Many women in this group meet diagnostic criteria for premenstrual Dysphoric Disorder (PMDD). Among women who suffer from PMDD, mood and behavioral symptoms such as irritability, depressed mood, tension, and labile mood dominate. Somatic complaints, including breast tenderness and bloating, also can prove disruptive to women's overall functioning and quality of life. Recent evidence suggests that individual sensitivity to cyclical variations in levels of gonadal hormones may predispose certain women to experience these mood, behavioral, and somatic symptoms. Treatments include: antidepressants of the serotonin reuptake inhibitor class, taken intermittently or throughout the menstrual cycle; medications that suppress ovarian cyclicity; and newer oral contraceptives with novel progestins.

  • are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome premenstrual Dysphoric Disorder
    CNS Drugs, 2006
    Co-Authors: Uriel Halbreich, Kimberly A Yonkers, Elias Eriksson, Torbjorn Backstrom, P Shaughn M Obrien, Ellen W Freeman
    Abstract:

    Current evidence suggests that the accepted treatments for premenstrual syndrome (PMS)/premenstrual Dysphoric Disorder (PMDD) have similar overall efficacy. While these treatments are more effective than placebo, response rates associated with them are far from satisfactory (<60%), such that, irrespective of treatment modality, there remain a significant number of women who are unresponsive to current conventional pharmacological therapy.

  • treatment of premenstrual Dysphoric Disorder with a new drospirenone containing oral contraceptive formulation
    Contraception, 2005
    Co-Authors: Teri Pearlstein, Gloria Bachmann, Howard A Zacur, Kimberly A Yonkers
    Abstract:

    Abstract Purpose This multicenter, double-blind, placebo-controlled crossover study evaluated the efficacy of a new oral contraceptive (OC) formulation containing drospirenone 3 mg and ethinyl estradiol (EE) 20 ��g in treating symptoms of premenstrual Dysphoric Disorder (PMDD). Method The OC formulation or placebo was administered for 24 days in a 28-day cycle (24/4), rather than the usual 21-day active treatment, 7-day inert-pill regimen. Participants ( N =64) were randomized to either study treatment for three cycles and then after a washout period of one treatment-free cycle switched to the alternate treatment. Results The mean decrease from baseline for total Daily Record of Severity of Problems (DRSP) scores while using drospirenone/EE was significantly greater than for placebo (���12.47, 95% CI=���18.28, ���6.66; p Conclusion Drospirenone/EE, given in a 24/4 regimen, was superior to placebo for improving symptoms associated with PMDD.

  • pretreatment pattern of symptom expression in premenstrual Dysphoric Disorder
    Journal of Affective Disorders, 2005
    Co-Authors: Teri Pearlstein, Kimberly A Yonkers, Rana Fayyad, John A Gillespie
    Abstract:

    Abstract Background Use of intermittent dosing strategies for the treatment of premenstrual Dysphoric Disorder (PMDD) highlights the need for detailed empirical data on the onset, duration and pattern of symptom expression in women suffering from PMDD. Method Data were analyzed from 276 women who met DSM-IV criteria for PMDD and prospectively charted two menstrual cycles prior to commencing sertraline treatment. The presence and severity of PMDD symptoms were measured using the Daily Record of Severity of Problems (DRSP). Results The most frequent PMDD symptoms (moderate-to-severe for ≥3 days) included anger/irritability (76%), anxiety/tension (71%), tired/lethargic (58%), and mood swings (58%). Mean DRSP scores peaked at day −2 (2 days prior to the onset of menses), but the within-patient day of onset of PMDD-level symptoms was highly variable, differing from cycle-to-cycle by ≥4 days in 45% of women. Similarly, the within-patient duration of PMDD symptoms varied from cycle-to-cycle by 3 or more days in ≥50% of women. Depending on the criteria used, 1 day after the onset of menstruation, 34–46% of women continued to report moderate to severe symptoms. Limitation Women in this sample were recruited for participation in a treatment study, and the results may not generalize to women with PMDD in the community. Conclusion The results of this analysis found significant within-patient variability in the time-to-onset and offset of PMDD symptoms, as well as their duration. The temporal pattern and high degree of within-patient variability across menstrual cycles of PMDD symptoms may have treatment implications.

Ellen W Freeman - One of the best experts on this subject based on the ideXlab platform.

  • continuous oral levonorgestrel ethinyl estradiol for treating premenstrual Dysphoric Disorder
    Contraception, 2012
    Co-Authors: Uriel Halbreich, Richard Bergeron, Ellen W Freeman, Lee S Cohen, Andrea J. Rapkin, Gary S Grubb, Lynne Smith, Sebastian Mirkin, Ginger D Constantine
    Abstract:

    Abstract Background The study was conducted to investigate continuous daily levonorgestrel 90 mcg/ethinyl estradiol 20 mcg (LNG/EE) on premenstrual Dysphoric Disorder (PMDD). Study Design In this multicenter, randomized, double-blind, placebo-controlled study, women with PMDD received LNG/EE ( n =186) or placebo ( n =181) daily for 112 days and completed the Daily Record of Severity of Problems (DRSP). Results Mean DRSP change from baseline to late luteal phase was significantly greater with LNG/EE than placebo at the late luteal phase of the first estimated cycle (���30.52��1.73 [SE] vs. ���22.47��1.77; p Conclusions Continuous daily LNG 90 mcg/EE 20 mcg was well tolerated and may be useful for managing the physical, psychological and behavioral symptoms and loss of work productivity related to PMDD.

  • are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome premenstrual Dysphoric Disorder
    CNS Drugs, 2006
    Co-Authors: Uriel Halbreich, Kimberly A Yonkers, Elias Eriksson, Torbjorn Backstrom, P Shaughn M Obrien, Ellen W Freeman
    Abstract:

    Current evidence suggests that the accepted treatments for premenstrual syndrome (PMS)/premenstrual Dysphoric Disorder (PMDD) have similar overall efficacy. While these treatments are more effective than placebo, response rates associated with them are far from satisfactory (<60%), such that, irrespective of treatment modality, there remain a significant number of women who are unresponsive to current conventional pharmacological therapy.

  • premenstrual syndrome and premenstrual Dysphoric Disorder definitions and diagnosis
    Psychoneuroendocrinology, 2003
    Co-Authors: Ellen W Freeman
    Abstract:

    Because of the prevalence, chronicity and distress caused by premenstrual symptoms (PMS), diagnosis and effective treatments are important information for clinicians. The DSM-IV requires at least five specified symptoms for premenstrual Dysphoric Disorder (PMDD), a severe Dysphoric form of PMS, while the ICD-10 requires only one distressing symptom for a diagnosis of PMS. Many women who seek treatment fall between these two diagnostic approaches, and standard diagnostic criteria for clinically significant PMS are needed. A diagnosis of PMS consists of determining the timing of the symptoms in relation to menses, meaningful change between post- and premenstrual symptom severity and a clinically significant severity of the symptoms. A differential diagnosis to distinguish PMS from other medical and psychiatric conditions is important for appropriate treatment. No hormone or laboratory test indicates a PMS diagnosis. The current diagnostic standard requires confirmation of subjective symptom reports by prospective daily diaries. Diagnostic criteria for PMS must recognize the broad range of symptoms, the temporal pattern of the symptoms and the critical issue of symptom severity, which differentiates clinically significant PMS from normal menstrual cycle changes.

  • efficacy of intermittent luteal phase sertraline treatment of premenstrual Dysphoric Disorder
    Obstetrics & Gynecology, 2002
    Co-Authors: Uriel Halbreich, Kimberly A Yonkers, Richard Bergeron, Ellen W Freeman, Anna L Stout, Lee S Cohen
    Abstract:

    Abstract OBJECTIVE: Premenstrual Dysphoric Disorder is a menstrually related Disorder that intermittently causes disabling emotional, behavioral, and physical symptoms. The goal of the current study was to evaluate the efficacy and tolerability of sertraline for premenstrual Dysphoric Disorder when treatment was limited to the luteal phase. METHODS: Two hundred eighty-one women who met Diagnostic and Statistical Manual of Mental Disorders (4th edition) criteria for premenstrual Dysphoric Disorder and who completed two prospective screening cycles and one single-blind placebo cycle were randomized to three cycles of double-blind, luteal phase treatment with either a placebo or sertraline in a flexible daily dose of 50–100 mg. Outcome measures included the Daily Record of Severity of Problems and the Clinical Global Impression Severity and Improvement scales. RESULTS: Luteal phase treatment with sertraline was significantly superior to the placebo, as demonstrated by end- point analysis of Clinical Global Impression Improvement scale scores (sertraline, 2.3 ± 1.1, versus placebo, 2.7 ± 1.1; P CONCLUSION: Sertraline was significantly more effective than a placebo and was well tolerated as a treatment for premenstrual Dysphoric Disorder when administered intermittently during the luteal phase of the menstrual cycle.

  • premenstrual daily fluoxetine for premenstrual Dysphoric Disorder a placebo controlled clinical trial using computerized diaries
    Obstetrics & Gynecology, 2002
    Co-Authors: Lee S Cohen, Uriel Halbreich, Ellen W Freeman, Cherri M Miner, Eileen Brown, Karen Sundell, Susan Mccray
    Abstract:

    Abstract OBJECTIVE: To evaluate premenstrual daily dosing with fluoxetine for treatment of premenstrual Dysphoric Disorder. METHODS: After a two-cycle screening and one-cycle single-blind placebo period, 260 women were randomized to fluoxetine 10 mg, fluoxetine 20 mg, or placebo (dosed daily from 14 days before next expected menses through the first full day of bleeding) for three cycles. Women recorded premenstrual Dysphoric Disorder symptoms daily using a computerized version of the Daily Record of Severity of Problems. RESULTS: Premenstrual daily fluoxetine 20 mg demonstrated significant improvement in mean Daily Record of Severity of Problems luteal scores compared with placebo (P = .005); premenstrual daily fluoxetine 10 mg did not (P = .100). Daily Record of Severity of Problems total scores were statistically significantly improved by the first treatment cycle for both active treatment groups. However, only fluoxetine 20 mg remained statistically significantly superior to placebo throughout the active treatment phase of the trial. Both fluoxetine groups showed significant treatment advantage over placebo for mood-related symptoms (P CONCLUSION: Premenstrual daily dosing with fluoxetine effectively treats mood, physical, and social functioning symptoms associated with premenstrual Dysphoric Disorder. Fluoxetine 20 mg appears to have comparable tolerability with, and better efficacy than, fluoxetine 10 mg.

Teri Pearlstein - One of the best experts on this subject based on the ideXlab platform.

  • premenstrual Dysphoric Disorder
    Medical Clinics of North America, 2019
    Co-Authors: Teresa Lanza Di Scalea, Teri Pearlstein
    Abstract:

    Premenstrual Dysphoric Disorder (PMDD) comprises emotional and physical symptoms and functional impairment that lie on the severe end of the continuum of premenstrual symptoms. Women with PMDD have a differential response to normal hormonal fluctuations. This susceptibility may involve the serotonin system, altered sensitivity of the GABAA receptor to the neurosteroid allopregnanalone, and altered brain circuitry involving emotional and cognitive functions. Serotonin reuptake inhibitors are considered the first-line treatment. Second-line treatments include oral contraceptives containing drospirenone, other ovulation suppression methods, calcium, chasteberry, and cognitive-behavioral therapy.

  • premenstrual Dysphoric Disorder burden of illness and treatment update
    FOCUS, 2012
    Co-Authors: Teri Pearlstein, Meir Steiner
    Abstract:

    Five percent of menstruating women have severe premenstrual symptoms and impairment of functioning defined as premenstrual Dysphoric Disorder (PMDD). Clinically significant premenstrual symptoms occur in at least an additional 20% of menstruating women. The diagnosis of PMDD should be confirmed by prospective symptom charting over 2 menstrual cycles to confirm the timing of the symptoms and to rule out other diagnoses. The burden of illness of PMDD includes disruption of parenting and partner relationships and decreased productivity in work roles. In addition, women with PMDD have increased use of health care services such as clinician visits and increased use of prescription medications and over-the-counter preparations. The etiology of PMDD is multifactorial. In particular, dysregulation of the serotonin and allopregnanolone systems is implicated. Several effective treatment options exist, including serotonergic antidepressant medications and an oral contraceptive that contains ethinyl estradiol and dro...

  • premenstrual Dysphoric Disorder burden of illness and treatment update
    Journal of Psychiatry & Neuroscience, 2008
    Co-Authors: Teri Pearlstein, Meir Steiner
    Abstract:

    Five percent of menstruating women have severe premenstrual symptoms and impairment of functioning defined as premenstrual Dysphoric Disorder (PMDD). Clinically significant premenstrual symptoms occur in at least an additional 20% of menstruating women. The diagnosis of PMDD should be confirmed by prospective symptom charting over 2 menstrual cycles to confirm the timing of the symptoms and to rule out other diagnoses. The burden of illness of PMDD includes disruption of parenting and partner relationships and decreased productivity in work roles. In addition, women with PMDD have increased use of health care services such as clinician visits and increased use of prescription medications and over-the-counter preparations. The etiology of PMDD is multifactorial. In particular, dysregulation of the serotonin and allopregnanolone systems is implicated. Several effective treatment options exist, including serotonergic antidepressant medications and an oral contraceptive that contains ethinyl estradiol and drosperinone. In addition, other hormones that suppress ovulation, anxiolytics, cognitive therapy, chasteberry and calcium may be helpful.

  • treatment of premenstrual Dysphoric Disorder with a new drospirenone containing oral contraceptive formulation
    Contraception, 2005
    Co-Authors: Teri Pearlstein, Gloria Bachmann, Howard A Zacur, Kimberly A Yonkers
    Abstract:

    Abstract Purpose This multicenter, double-blind, placebo-controlled crossover study evaluated the efficacy of a new oral contraceptive (OC) formulation containing drospirenone 3 mg and ethinyl estradiol (EE) 20 ��g in treating symptoms of premenstrual Dysphoric Disorder (PMDD). Method The OC formulation or placebo was administered for 24 days in a 28-day cycle (24/4), rather than the usual 21-day active treatment, 7-day inert-pill regimen. Participants ( N =64) were randomized to either study treatment for three cycles and then after a washout period of one treatment-free cycle switched to the alternate treatment. Results The mean decrease from baseline for total Daily Record of Severity of Problems (DRSP) scores while using drospirenone/EE was significantly greater than for placebo (���12.47, 95% CI=���18.28, ���6.66; p Conclusion Drospirenone/EE, given in a 24/4 regimen, was superior to placebo for improving symptoms associated with PMDD.

  • pretreatment pattern of symptom expression in premenstrual Dysphoric Disorder
    Journal of Affective Disorders, 2005
    Co-Authors: Teri Pearlstein, Kimberly A Yonkers, Rana Fayyad, John A Gillespie
    Abstract:

    Abstract Background Use of intermittent dosing strategies for the treatment of premenstrual Dysphoric Disorder (PMDD) highlights the need for detailed empirical data on the onset, duration and pattern of symptom expression in women suffering from PMDD. Method Data were analyzed from 276 women who met DSM-IV criteria for PMDD and prospectively charted two menstrual cycles prior to commencing sertraline treatment. The presence and severity of PMDD symptoms were measured using the Daily Record of Severity of Problems (DRSP). Results The most frequent PMDD symptoms (moderate-to-severe for ≥3 days) included anger/irritability (76%), anxiety/tension (71%), tired/lethargic (58%), and mood swings (58%). Mean DRSP scores peaked at day −2 (2 days prior to the onset of menses), but the within-patient day of onset of PMDD-level symptoms was highly variable, differing from cycle-to-cycle by ≥4 days in 45% of women. Similarly, the within-patient duration of PMDD symptoms varied from cycle-to-cycle by 3 or more days in ≥50% of women. Depending on the criteria used, 1 day after the onset of menstruation, 34–46% of women continued to report moderate to severe symptoms. Limitation Women in this sample were recruited for participation in a treatment study, and the results may not generalize to women with PMDD in the community. Conclusion The results of this analysis found significant within-patient variability in the time-to-onset and offset of PMDD symptoms, as well as their duration. The temporal pattern and high degree of within-patient variability across menstrual cycles of PMDD symptoms may have treatment implications.

Inger Sundstromporomaa - One of the best experts on this subject based on the ideXlab platform.